View Older Stories

May 13, 2026 08:02AM UroGen reports 64.5% three-year response rate for ZUSDURI bladder cancer drug

May 11, 2026 07:12AM UroGen Pharma (URGN) PT Raised to $45 at H.C. Wainwright

May 11, 2026 06:36AM Ladenburg Thalmann Assumes UroGen Pharma (URGN) at Buy

May 6, 2026 08:04AM UroGen Pharma (URGN) Tops Q1 EPS by 3c

Apr 9, 2026 04:18PM Jefferies Starts UroGen Pharma (URGN) at Buy

Mar 30, 2026 08:05AM UroGen publishes 24-month ZUSDURI trial data in Journal of Urology

Mar 3, 2026 07:31AM UroGen Pharma (URGN) PT Raised to $34 at Oppenheimer

Mar 2, 2026 11:20AM Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN) "We Buy the Weakness"

Mar 2, 2026 08:40AM UroGen Pharma (URGN) Misses Q4 EPS by 6c

Mar 2, 2026 08:04AM UroGen launches ZUSDURI as revenue rises 21% in 2025

Mar 2, 2026 07:55AM UroGen refinances debt with Pharmakon at 8.25% fixed rate

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Nov 6, 2025 09:17AM UroGen Pharma (URGN) PT Raised to $30 at D. Boral Capital

Nov 6, 2025 08:21AM UroGen Pharma (URGN) Misses Q3 EPS by 1c

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 2, 2025 08:02AM UroGen publishes clinical review of ZUSDURI for bladder cancer treatment

Aug 19, 2025 06:18AM Piper Sandler Starts UroGen Pharma (URGN) at Overweight

Aug 14, 2025 11:01AM TD Cowen on UroGen Pharma (URGN): 'The Early Launch Is Ramping Nicely & 2026 Should Inflect'

Aug 11, 2025 06:39AM UroGen Pharma (URGN) PT Lowered to $40 at H.C. Wainwright

Aug 8, 2025 08:33AM UroGen Pharma (URGN) PT Raised to $32 at Guggenheim

Aug 7, 2025 08:16AM UroGen Pharma (URGN) Misses Q2 EPS by 22c

Jul 21, 2025 08:05AM UroGen's bladder cancer drug shows 3.5-year response in study

Jul 9, 2025 09:41AM Increasing unusual put option volume: AEHR PL PRMB AGNC URGN

Jul 8, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)

Jul 7, 2025 08:04AM UroGen completes enrollment in phase 3 bladder cancer drug trial

Jun 16, 2025 06:34AM H.C. Wainwright Upgrades UroGen Pharma (URGN) to Buy

Jun 15, 2025 10:41PM ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN

Jun 15, 2025 06:07AM URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before Expiration of July 28 Class Action Deadline

Jun 13, 2025 03:16PM UroGen Pharma (URGN) PT Raised to $31 at Oppenheimer

Jun 13, 2025 03:10PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN

Jun 13, 2025 10:30AM URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Jun 13, 2025 07:46AM URGN CLASS ACTION NEWS: UroGen Pharma Ltd. Shareholders that Suffered Losses are Alerted of the Upcoming July 28 Securities Fraud Class Action Deadline

Jun 13, 2025 07:17AM UroGen Pharma (URGN) PT Raised to $47 at Scotiabank

Jun 13, 2025 07:16AM UroGen Pharma (URGN) PT Raised to $30 at Guggenheim

Jun 12, 2025 04:00PM URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Jun 12, 2025 01:28PM UroGen Pharma (URGN) Announces FDA Approval of ZUSDURI for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jun 11, 2025 04:03PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN

Jun 11, 2025 03:41PM URGN LEGAL ALERT: BFA Law Notifies UroGen Pharma Ltd. Investors of the Imminent July 28 Securities Fraud Class Action Deadline

Jun 11, 2025 01:45PM Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN

Jun 10, 2025 06:41PM UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman

Jun 10, 2025 03:36PM URGN LEGAL NEWS: UroGen Pharma Ltd. Investors with Losses are Notified to Contact BFA Law about the Pending Class Action Lawsuit

Jun 9, 2025 07:46AM URGN INVESTOR REMINDER: BFA Law Reminds UroGen Pharma Ltd. Investors to Contact the Firm by the July 28 Class Action Deadline

Jun 8, 2025 01:30PM URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Jun 8, 2025 08:17AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 8, 2025 07:03AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN

Jun 7, 2025 07:52AM Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN

Jun 7, 2025 07:08AM URGN INVESTOR ALERT: UroGen Pharma Ltd. Shareholders are Notified to Contact BFA Law by the July 28 Securities Fraud Class Action Deadline

Jun 6, 2025 04:00PM URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Jun 5, 2025 05:50PM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 5, 2025 07:18AM URGN LAWSUIT DEADLINE: BFA Law Notifies UroGen Pharma Ltd. Investors to Contact the Firm before the July 28 Securities Class Action Deadline

View Older Stories